Shots: The P-III LELANTOS-2 study will assess Pamrevlumab + systemic corticosteroids vs PBO + systemic corticosteroids in ~70 patients aged 6-12yrs. in a ratio (1:1) with ambulatory DMD for up […]readmore
Tags : Second
Shots: The P-III U-ACCOMPLISH induction study involves assessing upadacitinib (45 mg, qd) vs PBO in patients with mod. to sev. UC The study met its 1EPs @8wks. i.e, patients achieved […]readmore
Shots: The enrollment of the first P-III study is currently underway & has reached 85% of its enrollment goal. In a P-II study of 336 patients, NOV03 met its 1EP […]readmore
Shots: Lilly’s partner Junshi has dosed the first healthy volunteer in a study evaluating JS016 to combat COVID-19. The study is being conducted by Junshi in China while Lilly to […]readmore
Shots: The US FDA has granted EUA to the BD’s molecular diagnostic test for COVID-19 that provides results in 2-3hrs. The BD SARS-CoV-2 Reagent Kit for BD MAX System has […]readmore
Shots: Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research, develop, manufacture and […]readmore
Shots: The Kite has submitted BLA to the US FDA for its investigational CAR T cell therapy, KTE-X19 for the treatment of r/r MCL The BLA submission is based on […]readmore
Shots: The second P-III SAkuraStar study involves assessing of Satralizumab (120 mg) as monothx. vs PBO in97 patients in a ratio (2:1) with AQP4-IgG seropositive or seronegative NMO and AQP4-IgG […]readmore
Shots: The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer The second phase of P-III MONALEESA-3 study resulted in meeting […]readmore
The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate […]readmore